Jornal de Carcinogênese e Mutagênese

Abstrato

Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy

Jing Sun, Shaohua He, Peinan Lin, Ping Li, Xiaomin Cai, Lele Li, Jing Qian, Chong Liu, Xiao Li, Yiqian liu, Oluf Dimitri Røe, Yongqian Shu, Xiaofeng Chen and Yanhong Gu

Objective: This retrospective study was carried out to compare the safety and efficacy of adjuvant capecitabine/ oxaliplatin (XELOX) versus capecitabine/paclitaxel (XP) in gastric cancer patients after D2 gastrectomy.

Methods: The hospital records of the First Affiliated Hospital of Nanjing Medical University from 2008-2012 were searched to identify patients treated with adjuvant XELOX or XP after D2 gastrectomy and their clinicopathological data were retrieved. Disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method with log-rank test.

Results: A total of 144 stage I-III patients who received adjuvant XELOX (n=89) or XP (n=55) after D2 gastrectomy were identified. The median follow-up time was 47.0 (25.0-80.0) months. The 3-year DFS and OS rate was 67.0% versus 50.8% (p=0.047) and 74.8% versus 63.5% (p=0.184) in the XELOX and XP group respectively. XELOX significantly reduced the risk of relapse at three years (HR 0.60, 95% CI 0.36-0.99) but did not reduced the risk of death at the third year (HR 0.66, 95% CI 0.36-1.22) compared with that treated with XP.

Conclusions: These results indicate that adjuvant XELOX after D2 gastrectomy has a clinical advantage over XP; however, prospective studies are needed to verify this finding.